drugset
drugset / Trial / NCT01504126

Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT01504126 ↗

Phase 0 Completed 32 enrolled M.D. Anderson Cancer Center National Cancer Institute (NCI) · collabSprint for Life · collab
NaSingle-groupOpen-labelTreatment

Summary

This early phase I trial studies giving propranolol hydrochloride with standard chemotherapy in treating patients with ovarian, primary peritoneal, or fallopian tube cancer. Biological therapies, such as propranolol hydrochloride, blocks certain chemicals that affect the heart and this may stimulate the immune system and allow the chemotherapy to kill more tumor cells.

Timeline

Start
2012-03-09
Primary completion
2019-08-15
Completion
2019-08-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Propranolol Small molecule — Oral

Indications

fallopian tube clear cell adenocarcinoma fallopian tube endometrioid adenocarcinoma fallopian tube mucinous adenocarcinoma fallopian tube serous adenocarcinoma ovarian clear cell adenocarcinoma ovarian endometrioid adenocarcinoma ovarian mucinous adenocarcinoma ovarian seromucinous carcinoma ovarian serous adenocarcinoma primary peritoneal serous adenocarcinoma undifferentiated ovarian carcinoma